The Effect and Mechanism of MMP-9 in Inducing Atherosclerosis
1 other identifier
observational
180
1 country
1
Brief Summary
The study will assess the serum expression of MMP-9 in normal people, type 2 diabetic patients and type 2 diabetic patients with atherosclerosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 7, 2020
CompletedFirst Posted
Study publicly available on registry
June 11, 2020
CompletedStudy Start
First participant enrolled
June 30, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2020
CompletedJune 11, 2020
June 1, 2020
5 months
June 7, 2020
June 8, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
total MMP-9 levels
the different group of total MMP-9 levels
6 months
Study Arms (3)
Normal people
No diabetes and atherosclerosis
type 2 diabetes mellitus without atherosclerosis
Newly diagnosed type 2 diabetes without atherosclerosis
type 2 diabetes mellitus with atherosclerosis
Newly diagnosed type 2 diabetes with atherosclerosis
Interventions
patients diagnosed as type 2 diabetes without atherosclerosis
patients diagnosed as type 2 diabetes with atherosclerosis
normal people without type 2 diabetes or atherosclerosis
Eligibility Criteria
Normal control group, newly diagnosis of type 2 diabetes mellitus with atherosclerosis, newly diagnosis of type 2 diabetes mellitus without atherosclerosis
You may qualify if:
- volunteer to participate and be able to sign informed consent prior to the trial.
- patients with type 2 diabetes, aged 18-60 years old, meeting WHO1999 diagnostic criteria, have not used any drugs.
- The patients have completed carotid ultrasound during hospitalization.
You may not qualify if:
- patients with any antidiabetic drugs.
- impaired liver and kidney function with ALT 2.5 times higher than the upper limit of normal value; Serum creatinine was 1.3 times higher than the upper limit of normal.
- drug abuse and alcohol dependence in the past 5 years.
- systemic hormone therapy was used in the last three months.
- patients with infection and stress within 4 weeks.
- any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Majianhualead
Study Sites (1)
Nanjing First Hospital
Nanjing, Jiangsu, China
Related Publications (1)
Liu B, Su L, Loo SJ, Gao Y, Khin E, Kong X, Dalan R, Su X, Lee KO, Ma J, Ye L. Matrix metallopeptidase 9 contributes to the beginning of plaque and is a potential biomarker for the early identification of atherosclerosis in asymptomatic patients with diabetes. Front Endocrinol (Lausanne). 2024 Apr 10;15:1369369. doi: 10.3389/fendo.2024.1369369. eCollection 2024.
PMID: 38660518DERIVED
Biospecimen
Serum for testing the MMP-9 level
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Head of Department of Endocrinology
Study Record Dates
First Submitted
June 7, 2020
First Posted
June 11, 2020
Study Start
June 30, 2020
Primary Completion
November 30, 2020
Study Completion
December 30, 2020
Last Updated
June 11, 2020
Record last verified: 2020-06